Conditions: Primary Myelofibrosis (MF)
Keywords: Post-Polycythemia Vera (PV) MF Post-Essential Thrombocythemia (ET) MF
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.

Detailed description:

Arms:
arm 1: Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.

Interventions: intervention 1: Ruxolitinib
Intervention descriptions: intervention 1: None

Protocol document: